Literature DB >> 30766011

Biosimilars: Considerations for Payers.

James Smeeding, Daniel C Malone, Monica Ramchandani, Bradley Stolshek, Larry Green, Philip Schneider.   

Abstract

Evaluating biosimilars requires payers to go beyond cost considerations: safety and efficacy, reliability of supply and logistics, and the impact of state laws on substitution and interchangeability must all be deliberated.

Keywords:  Biosimilars; affordability and access; benefit management; managed care; payers; pharmacoeconomics

Year:  2019        PMID： 30766011      PMCID： PMC6355057     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  11 in total

Review 1.  Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.

Authors:  Jacobus R B J Brouwers; Jeanine E Roeters van Lennep; Maarten J Beinema
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

2.  Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.

Authors:  Elizabeth Lerner Papautsky; Martha Carlson; Sheila M Johnson; Hannah Montague; Deanna J Attai; Maryam B Lustberg
Journal:  Breast Cancer Res Treat       Date:  2022-05-14       Impact factor: 4.624

Review 3.  Update on Biosimilar Insulins: A US Perspective.

Authors:  Rong M Zhang; Ritika Puri; Janet B McGill
Journal:  BioDrugs       Date:  2020-08       Impact factor: 7.744

4.  Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.

Authors:  Abduzhappar Gaipov; Alpamys Issanov; Zhanar Mursalova; Nazia Tulegenova; Zoya Kakim; Mukhit Baizakov; Saltanat Tuganbekova; Mohamad Aljofan
Journal:  Pharmacol Res Perspect       Date:  2020-06

Review 5.  The Clinical Implications of Nocebo Effects for Biosimilar Therapy.

Authors:  Luana Colloca; Remo Panaccione; T Kevin Murphy
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 6.  Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?

Authors:  Antoine Perpoil; Gael Grimandi; Stéphane Birklé; Jean-François Simonet; Anne Chiffoleau; François Bocquet
Journal:  Int J Environ Res Public Health       Date:  2020-12-29       Impact factor: 3.390

Review 7.  Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.

Authors:  Kelley D Mayden; John M Kelton; Joanne C Ryan; Ali McBride
Journal:  J Adv Pract Oncol       Date:  2022-06-21

Review 8.  Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.

Authors:  Hans-Christian Kolberg; Marco Colleoni; Patricia Santi; Georgia Savva Demetriou; Miguel Angel Segui-Palmer; Yasuhiro Fujiwara; Sara A Hurvitz; Vladimir Hanes
Journal:  Target Oncol       Date:  2019-12       Impact factor: 4.493

Review 9.  Current and future roles of biosimilars in oncology practice.

Authors:  Sofia Konstantinidou; Angeliki Papaspiliou; Eleni Kokkotou
Journal:  Oncol Lett       Date:  2019-11-15       Impact factor: 2.967

10.  Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Authors:  Yujeong Kim; Hye-Young Kwon; Brian Godman; Evelien Moorkens; Steven Simoens; SeungJin Bae
Journal:  Front Pharmacol       Date:  2020-07-09       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.